Tempus Buys Personalis for $1.5 Billion to Chase Natera’s MRD Lead

Tempus AI agreed to pay $16.25 a share for the roughly four-fifths of Personalis it does not already own, a deal that values the cancer monitoring specialist at $1.5 billion in enterprise value. The all-stock transaction converts a three-year commercial partnership into full ownership. It hands Tempus control of a blood test built to catch cancer recurrence before a scan ever could.

Tempus founder and chief executive Eric Lefkofsky and chief financial officer Jim Rogers walked investors through the numbers on a special call Monday morning. The pitch was straightforward: molecular residual disease testing, known as MRD, tracks fragments of tumor DNA circulating in a patient’s blood after treatment, and the market for it is exploding. The complication is that Tempus is buying its way into a field where one rival already has the volume Personalis has spent years trying to reach.

Tempus Pays $16.25 a Share for the Company It Already Part Owns

Personalis shareholders will get $16.25 per common share, a 6% premium to Friday’s closing price and a 28% premium to the unaffected 30-day volume-weighted average price, or VWAP. Run the percentages backward and Personalis was trading near $15.33 on Friday, up from an unaffected average closer to $12.70 a month earlier, a run that suggests deal chatter had already lifted the stock before Monday’s announcement.

The consideration is structured as 100% stock, with Tempus holding an option to pay up to half in cash at its own discretion. Personalis holders get a floating exchange ratio of Tempus shares, capped at a maximum of 0.3356, to be finalized closer to closing. Cash, if Tempus chooses to use it, comes from cash on hand and borrowings under its existing credit facilities.

Tempus is not a stranger to this cap table. It exercised warrants and bought shares for a 19.3% stake in Personalis back in August 2024, spending roughly $36 million in the process. This deal buys the remaining stock it does not control, and both companies’ boards have already signed off.

The Premium Trails a Price Target Wall Street Set Days Earlier

Here is the part that undercuts the tidy premium math. On July 17, three days before the deal was announced and the same Friday the offer price is benchmarked against, Needham raised its price target on Personalis to $17 from $12, according to analyst-action tracking published on CNN’s markets page. That target sits above the $16.25 Tempus is actually paying.

The same tracking shows Wall Street had turned more bullish on Tempus itself in the run-up to the deal. Guggenheim lifted its Tempus target to $65 from $60 on July 16. TD Cowen moved to $71 from $68 on July 15. Bank of America, more cautious, kept a Hold rating on July 13. None of those targets anticipated a $1.5 billion outlay for a company generating $22.4 million a quarter.

There’s a profitability wrinkle too. Simply Wall St’s tracking of the 14 analysts who cover Tempus shows consensus has moved from an expected $17 million profit in 2028 to a projected $53.4 million loss, as growth assumptions soften. A company not yet reliably profitable is now committing a sum equal to a meaningful slice of its own market value to a single acquisition.

Natera’s Signatera Still Owns This Market

Tempus calls MRD a $20 billion opportunity, and the underlying growth is real. But the company that already owns most of it isn’t Personalis. Natera’s Signatera test carries more than 90% share of the MRD market and over $1 billion in annualized revenue growing above 70% a year, according to an RBC Capital note issued in June that accompanied a price target increase to $275.

The scale gap shows up in the numbers each company actually reports.

Natera processed roughly 21 times as many MRD tests in a single quarter as Personalis did, based on those fourth-quarter 2025 test volumes disclosed to the SEC. Its momentum has kept building. Trade coverage reported Natera’s first-quarter 2026 revenue jumped to $696.6 million, well above analyst estimates, and the stock climbed after clinical guideline bodies gave Signatera a top-tier recommendation in bladder cancer this June.

From Minority Investor to Full Owner in Three Years

The path here did not start with a buyout offer. It started with a lab test and a handshake.

1. November 2023: Personalis and Tempus Labs announced a strategic collaboration to co-commercialize NeXT Personal Dx for MRD testing in lung and breast cancer.
2. August 2024: Tempus exercised warrants and bought additional shares for about $36 million, building a 19.3% stake and agreeing to vote those shares however the majority of Personalis’s own board recommended, a commitment that ran through the end of 2025.
3. July 2025: The companies expanded their exclusive commercial agreement to add colorectal cancer as a fourth covered indication.
4. July 2026: Tempus signed a definitive agreement to acquire every remaining share of Personalis it does not already own.

That 2024 voting commitment is worth sitting with. Tempus went out of its way then to look like a passive investor rather than a controlling one. Two years later, it is buying the whole company outright.

What Still Has to Happen Before This Deal Closes?

The deal needs a Personalis shareholder vote, regulatory clearance and a joint going-private style filing, and it can still fall apart if Tempus stock drops too far before closing. That is not unusual for a stock merger, but the combination here carries extra scrutiny because the buyer is already an insider.

• Approval from Personalis shareholders on the merger agreement itself.
• Standard antitrust and other regulatory approvals.
• A jointly filed Schedule 13E-3, the disclosure regulators require when an existing affiliate takes a company private, meant to give unaffiliated shareholders extra protection and information.
• Tempus’s Class A stock staying above $46 through closing; if it falls below that level, Personalis gains the right to walk away.
• Other customary closing conditions typical of a merger this size.

Closing is expected in late 2026 or early 2027. The Schedule 13E-3 requirement exists specifically because Tempus already owns a chunk of the company it’s buying, and regulators treat affiliate buyouts differently than arm’s length ones for exactly that reason.

MRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored, helping clinicians make faster and more informed decisions when cancer recurs.

Lefkofsky made that case on the call, framing the deal as the natural next step after two years of co-commercialization. Personalis chief executive Chris Hall struck a similar note, saying the company ran an “exhaustive process” and concluded Tempus’s offer gave shareholders “the fastest path” to scaling its tests.

The Monitoring Math Behind a $20 Billion Market

Strip away the deal mechanics and the underlying demand argument holds up. Cancer survivorship is getting longer, and every survivor needs someone watching for recurrence.

• 2.1 million: new cancer diagnoses expected in the United States this year, per the American Cancer Society’s 2026 facts and figures report.
• $20 billion: the MRD market opportunity Tempus itself cited in announcing the deal.
• 33%: quarter-over-quarter growth in Personalis’s clinical test volume last quarter alone.
• Three: the number of indications where Medicare already covers NeXT Personal, with more coverage decisions expected.

Personalis isn’t standing still on indications either. Its NeXT Personal test picked up colorectal cancer as a covered use in mid-2025, part of a push to bring ultra-sensitive recurrence testing to more cancer types. Tempus, for its part, has been building through acquisition before this one, having added pharmacogenomics company Oneome in November 2025. Personalis is by far the largest bet in that pattern.

Frequently Asked Questions

What Will Personalis Shareholders Actually Receive?

Personalis holders get Tempus stock under a floating exchange ratio capped at 0.3356 shares, plus the option for Tempus to pay up to half the consideration in cash. Because the ratio finalizes closer to closing, the value shareholders ultimately receive could differ from the $16.25 headline figure depending on where Tempus stock trades then.

What Is Molecular Residual Disease Testing?

Molecular residual disease testing looks for tiny fragments of tumor DNA, called circulating tumor DNA, that remain in a patient’s blood after cancer treatment. Finding it can signal that cancer is still present or returning, often months before it would show up on a scan, which is why tests like NeXT Personal and Signatera are built around detecting it at extremely low concentrations.

Why Can Personalis Walk Away if Tempus Stock Falls Below $46?

Because the deal is paid mostly in Tempus stock, a big drop in Tempus’s share price before closing would shrink the real value Personalis shareholders receive. The $46 floor is downside protection built into the merger agreement, giving Personalis the right to terminate rather than close a deal that has quietly become worth much less than advertised.

Will Personalis Keep Trading on Nasdaq?

Not once the deal closes. Tempus is acquiring every outstanding share of Personalis it doesn’t already hold, so Personalis common stock, listed under PSNL, would stop trading independently after shareholder and regulatory approvals clear, expected in late 2026 or early 2027.

How Does the $20 Billion MRD Market Compare to What’s Already Being Captured?

Even Natera, the category leader, reported about $2.3 billion in total 2025 revenue, and Signatera accounts for a large share of that. Against a cited $20 billion opportunity, the category is still in its early innings, which is the growth case Tempus is buying into even as it starts from far behind the leader.

Disclaimer: This article is for informational purposes only and is not investment or medical advice; the transaction remains subject to shareholder and regulatory approval, and all figures reflect publicly available information as of publication.